Highlights Moderna, Inc.

Equities

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-16 pm EST			5-day change	1st Jan Change
41.83 ^USD	+6.28%		+21.95%	+41.84%

Jan. 16	Sector Update: Health Care Stocks Retreat Late Afternoon	MT
Jan. 16	Sector Update: Health Care Stocks Softer Friday Afternoon	MT

Highlights

Jan. 16	Arbutus Biopharma Says European Patent Office Revokes Patent; Shares Fall	MT
Jan. 16	Arbutus Biopharma Corp - EPO revokes Arbutus Biopharma's European patent EP 2279254 - SEC filing	RE
Jan. 13	PRESS DIGEST- Financial Times - January 13	RE
Jan. 12	Moderna Sees 2025 Revenue Close to Outlook Range, Affirms Growth Target For This Year	MT
Jan. 12	Moderna Expects 2025 Revenue of $1.9 Billion	MT
Jan. 12	(MRNA) Moderna Expects 2025 Revenue About $1.9B, vs. FactSet Est of $1.91B	MT
Jan. 12	Moderna expects 2025 revenue of about $1.9 billion	RE
Jan. 12	Moderna expects $1.9 billion in sales, trims costs forecast for 2025	RE
Jan. 07	Bayer Unit Sues Pfizer, BioNTech, Moderna for Technology Misuse in COVID-19 Vaccine Production	MT
Jan. 07	Geopolitics Tests the Rally
Jan. 07	Bayer's Monsanto Sues Pfizer, Over COVID Vaccine Makers Over mRNA Technology Patents	MT
Jan. 07	Bayer Unit Sues Pfizer, BioNTech, Moderna for Technology Misuse in COVID-19 Vaccine Production	MT
Jan. 07	Bayer's Monsanto Sues Pfizer, Over COVID Vaccine Makers Over mRNA Technology Patents	MT
Jan. 07	Bayer Sues Biontech and Pfizer Over Patents for Covid Vaccines	RE
Jan. 07	Bayer Unit Sues Pfizer, BioNTech, Moderna for Technology Misuse in COVID-19 Vaccine Production	MT
Jan. 06	Bayer Unit Sues Pfizer, BioNTech, Moderna for Technology Misuse in COVID-19 Vaccine Production	MT
Jan. 06	Bayer sues COVID vaccine makers over mRNA technology	RE
Jan. 05	Moderna Seeks Marketing Authorization for Influenza Vaccine	MT
Dec. 12	US FDA Considering 'Black Box' Warning for COVID-19 Vaccines	MT
Dec. 12	GSK gets EU regulator backing for expanded use of RSV vaccine	RE
Dec. 11	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth At 2025 Investor Day	CI
Dec. 11	Nanexa Grants Moderna License to Use PharmaShell Drug Delivery Platform with First Compound	MT
Dec. 10	Nanexa AB and Moderna Enter into License and Option Agreement for the Development of Pharmashell-Based Products	CI
Nov. 24	Phenomenal Value Destruction at Moderna
Nov. 20	Health Care Down, But not by Much, Amid Deal Activity -- Health Care Roundup	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Moderna Falls As FDA Vows To Impose New Vaccine Rules

December 01, 2025 at 03:32 pm EST

Phenomenal Value Destruction at Moderna

November 24, 2025 at 08:44 am EST